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Abstract 
Understanding the therapeutic effects of diabetes medications is an essential aspect of ongoing care for 
maintaining wellness and reducing early readmission (< 30 days). We analysed comorbid diabetic patients 
to establish the impacts of medication dosage on their readmission predisposition. After statistically 
analysing 101,766 patients’ records with Analysis of Variance (ANOVA), Students’ t-test with Bonferroni-
Holm correction, and multivariate logistics regression, we affirmed that metformin, insulin, and 
repaglinide administered dosages significantly influence readmission at 95% confidence level. This result 
shows that therapeutic dosages influence “< 30 days” and “No” readmissions for those treated with insulin 
and metformin while those treated with repaglinide are impacted on “< 30 days” and “> 30 days” 
readmissions. This finding opens a new frontier to study the factors influencing unplanned readmissions 
for comorbid diabetic patients treated with these medications.  
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Introduction 
Given the pressures on hospitals to reduce costs, improve care, lower the length of stay (LOS) and 
decrease unplanned readmission, it becomes prudent to assess groups of patients at high risk. One such 
group is comorbid diabetic patients and thus, we focus on answering the research question− How can we 
better understand medication therapy and readmission of comorbid diabetic patients.  
Prediction of readmission risks will help in reshaping the healthcare industry due to the reliance of 
some clinical decisions on the susceptibility of patients to early readmission (< 30 days). Readmission 
information has been used as the source of resource allocation and distribution amongst patients in 
hospitals (Kansagara et al. 2011) to ensure that appropriate care level is implemented (Jack et al. 2009). To 
this end, it has acted as the dossier for designing and implementing person-centred care and provided data 
for quick and effective interventions for high-risk patients. The likelihood that lives will be saved, and 
emergency departments decongested (Cai et al. 2015) when readmission risk enablers are known in advance 
is high since the proper allocation of resources to patients will culminate in the timeliness of care. This will 
also result in reduced risk of hospital infections and multiplicity of comorbidities while minimizing dying 
after discharge (Kansagara et al. 2011, Cai et al. 2015).  
Researchers have studied patients’ risk of early readmission using pathological reports, clinical and 
socio-economic factor makers (Amarasingham et al. 2013), and psychosocial factors such as dementia, 
depression, medication adherence, declining of services, and missed clinical appointments (Watson et al. 
2011). These studies highlighted the importance of using Electronic Medical Records (EMRs) for patients’ 
generic risk scoring despite their disease conditions (Hao et al. 2015) while others have streamlined risk-
scoring to selected diseases (Amarasingham et al. 2013, Sivritepe et al. 2019). Although previous 
hospitalization, ageing, and socioeconomic conditions are relevant factors contributing to the early 
readmission of diabetes patients (Robbins et al. 2019), acute and chronic glycaemic control have also been 
linked to reduced hospitalization of these patients (Dungan 2012). Mingle (2017) showed that improving 
readmission of diabetes patients requires a wide blend of clinical and demographic features and affirmed 
that reducing the biases associated with patients’ age enhances readmission prediction. Bhuvan et al. (2016) 
concluded that the number of inpatient visits, discharge disposition and admission type were among the 
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influencing factors of early readmission while Eby et al. (2015) showed that comorbidities associated with 
heart failure also contributes. 
Since researchers have limited focus on medication therapy and unplanned readmission, we decided 
to explore the potentials of reducing early unplanned readmission for certain comorbidities. Treating 
comorbid diabetic patients with different dosages of medication therapies could significantly influence their 
wellness as less individualization of dosing can result in toxicity and reduced therapeutic response 
(MacCallum 2014). Thus, it became imperative to understand if the variability in therapeutic dosages and 
change in administered medications have any effect on readmission susceptibility. To this end, it was 
hypothesized that –  
- H1: The difference in administered dosages of medications resulted in varying therapeutic effects 
hence, influenced the readmission proneness of diabetic patients suffering from circulatory, 
respiratory, digestive, injury, musculoskeletal, genitourinary and neoplasms related comorbidities. 
- H2:  Medication change influenced the readmission proneness of diabetic patients suffering from 
circulatory, respiratory, digestive, injury, musculoskeletal, genitourinary and neoplasms related 
comorbidities. 
- H3: The Gender of circulatory, respiratory, digestive, injury, musculoskeletal, genitourinary and 
neoplasms comorbid diabetic patients treated with different medication therapies influenced their 
readmission predisposition. 
Method 
We focused on a quantitative research methodology of secondary data analysis.    
Data acquisition 
This study relied on 10 years of data (1999-2008) from the Health Facts database of the (Cerner 
Corporation, Kansas City, MO, USA) that was reported by Strack et al. (2014) for the analysis. This data 
warehouse has clinical records of 130 hospitals and hosted over 70 million unique records of patients that 
were treated for diabetes and other associated comorbidities in different instances. These patients (Table 
1) had their dosages as steady, down or up. Hence, they maintained their usual dose of the medication 
(steady), medication dose was reduced (down) or there was an increase in dosage (up).  
Patients’ characteristics, diagnostic and hospital visitation features 
Age, mean(±SD) 65.97±16.21 
Time in hospital, mean(±SD) 4.40±2.99 
Number of lab procedures, mean(±SD) 43.10±19.67 
Number of procedures, mean(±SD) 1.34±1.71 
Number of medications, mean(±SD) 16.02±8.13 
Number of outpatient visits, mean(±SD) 0.37±1.27 
Number of emergency visits, mean(±SD) 0.20±0.93 
Number of inpatient visits, mean(±SD) 0.64±1.26 
Number of diagnoses, mean(±SD) 7.42±1.93 
Female (%) 53.76% 
Male (%) 46.24% 
Medication changed on admission (%) 46.20% 
Medication unchanged on admission (%) 53.80%  
Table 1: Some characteristics of diabetic patients treated with various medications 
These medications with the population of treated patients in brackets include –  
Acarbose (308), glimepiride (5191), glipizide (12686), glyburide (10650), glyburide-metformin (706), 
insulin (54383), metformin (19988), nateglinide (703), pioglitazone (7328), repaglinide (1539) and 
rosiglitazone (6365). 
The comorbidities were diagnosed by the treating health professionals and categorized into 8 main 
groups that include - circulatory, respiratory, digestive, injury, musculoskeletal, genitourinary, neoplasms 
and other diseases. Whereas the diseases represented any illness that affected the stated part of the body, 
“injury” was used for physical injury and poisoning, “others” captured diseases that cannot be directly 
grouped under the 7 main classes. Thus, covered conditions like symptoms and signs of infectious diseases, 
endocrinal, nutritional and immunity disorders, nervous system infections and cases of childbirth 
complications.  
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Statistical analysis 
Since these patients were treated with different doses of administered medications, it is important to 
understand if there exists any significant difference in the doses for the various readmission groups − “< 30 
days”, “> 30 days” and “No” readmissions. Whereas the “<30 days” readmission represents patients on 
early unplanned readmission, “>30 days” is for patients who returned after 30 days of discharge while the 
“No” readmission category was not back as inpatients within the period under consideration. We used a 
single-factor analysis of Variance (ANOVA) to establish if any variance exists in the medication doses 
administered to patients from the various readmission categories and implemented a Student’s t-test with 
Bonferroni-Holm correction Post hoc analysis. A multivariate logistics regression model was finally used to 
estimate the odds of readmission (OR) by adjusting for patients’, diagnostics, hospital visitation 
characteristics, and comorbidities.  
Results  
The summary of the single factor ANOVA test shown in Table 2 indicates that metformin, repaglinide, and 
insulin are statistically significant and Table 3 that considered these significant medications distinguishes 
the readmission categories in a Post hoc analysis. 
Medication F-statistics P-value 
Acarbose 0.0795 0.9236 
Glimepiride 1.0961 0.3342 
Glipizide 2.0358 0.1306 
Glyburide & metformin 0.5495 0.5775 
Insulin 4.0907 0.0167* 
Metformin 3.4018 0.0333* 
Nateglinide 0.3300 0.7191 
Pioglitazone 0.0762 0.9267 
Repaglinide 3.2237 0.0401* 
Rosiglitazone 0.4650 0.6282 
Table 2: Summary of a single factor ANOVA test to establish the statistical significance of 
administered dosage on readmission (bold* are significant at 95% confidence level) 
Table 3 shows a statistically significant difference for patients treated with insulin and metformin that were 
readmitted in < 30 days and those that were on “No” readmitted category whereas those treated with 
repaglinide have a statistical significant existing for those readmitted in “< 30 days” and “> 30 days”. 
Following this result, we can accept the null hypothesis (H1) as follows: 
 Insulin therapy for “No” readmission and “< 30 days” readmission; metformin for “No” readmission and 
“< 30 days” readmission and repaglinide for “> 30 days” readmission and “< 30 days” readmission.  
Those treated with metformin and insulin, the odds of readmission (OR) for the females is higher 
than males for “<30 days” and “>30 days” readmissions (13% - 26%) (see Table 4) but lower for “No” 
readmission (15% - 20%). Males treated with repaglinide have 29%-36% more odds of “No” readmission 
than returning in < 30 days or > 30 days of discharge. Men are more likely not to come back to the hospital 
when treated with repaglinide than women. However, women are more predisposed to “<30 days” and “>30 
days” readmission than men. Notwithstanding, males treated with metformin have 7% - 14% fewer chances 
of readmission in < 30 days than those treated with insulin and repaglinide. 
Readmission1 Readmission2 stat P value P adj Remark 
Insulin  
No  < 30 days 2.6274 0.0086 0.0167 Accept 
No > 30days 1.5966 0.1104 0.0250 Reject 
< 30 days  > 30days  -1.4921 0.1357 0.0500 Reject 
Metformin  
No < 30 days  2.5792 0.0100 0.0167 Accept 
No  > 30days 1.0158 0.3097 0.0500 Reject 
< 30 days  > 30days -1.8595 0.0630 0.0250 Reject 
Repaglinide  
No  < 30 days -1.3022 0.1937 0.0500 Reject 
No > 30days  1.5943 0.1111 0.0250 Reject 
< 30 days > 30days 2.4083 0.0166 0.0167 Accept 
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Table 3: Student’s t-test with Bonferroni-Holm estimation of significant readmission 
classifications (P adj: corrected P-value) 
Patients whose medications were changed during admission and were treated with metformin or 
insulin are more likely to be readmitted back in hospital than those that maintained their medications as 
insulin and metformin. When metformin or insulin is used for treating patients that were originally using 
them, they have 11% - 22% more chances of not returning to hospital admission. Moreover, patients that 
retained their repaglinide treatment have 16.32% more likelihood of readmission in >30 days than those 
treated with the medication as a new one on admission. The chances of “No” readmission for patients 
treated with repaglinide (changed) is 4.69% higher than those subjected to the medication newly on 
hospitalization. 
Parameter Type <30 days readmission >30 days readmission No readmission 
Metformin 
Gender 
Female 1.00 1.00 1.00 
Male 0.74 (0.68 to 0.81) 0.84 (0.80 to 0.90) 1.20 (1.14 to 1.27) 
Medication 
changed 
Yes 1.00 1.00 1.00 
No 0.81(0.80 to 0.91) 0.86(0.80 to 0.92) 1.16(0.92 to 1.25) 
Insulin 
Gender 
Female 1.00 1.00 1.00 
Male 0.81(0.77 to 0.86) 0.87 (0.84 to 0.90) 1.15(1.11 to 1.19) 
Medication 
changed 
Yes 1.00 1.00 1.00 
No 0.77(0.72 to 0.81) 0.8195 (0.79 to 0.85) 1.22 (1.17 to 1.26) 
Repaglinide 
Gender 
Female 1.00 1.00 1.00 
Male 0.89 (0.66 to 1.19) 0.82 (0.66 to 1.01) 1.18(0.96 to 1.45) 
Medication 
changed 
Yes 1.00 1.00 1.00 
No 0.75 (0.51 to 1.09) 1.16 (0.91 to 1.49) 0.95 (0.74 to 1.23) 
Table 4: Odds of readmission and 95% CI by gender and change in diabetes medication for 
patients treated with metformin, insulin, and repaglinide (CI: confidence interval) 
Implications for theory and practice 
Since the understanding of medication therapies have a significant influence on early unplanned 
readmission, practitioners can know some of the most potent therapies for managing different 
comorbidities. Thus, giving room for minimized LOS due to enhanced diagnosis and treatment that 
optimizes cost (Egede et al. 2012). Emphatically, there will be room for the implementation of coordinated 
preoperative screening and optimization using the knowledge garnered from the risk factors for judicious 
glycaemic control. This can improve patients’ outcomes, reduce complications, and mitigate the cost of 
managing diabetes (Stryker 2016). 
Conclusions  
This research in progress is looking at ways of remediating some of today’s healthcare challenges by 
focusing on how we might better manage the patient cohorts against 30 days unplanned readmission. We 
studied the effect of medication therapies on readmission of diabetic patients by analysing different 
medications used for treating patients with circulatory, respiratory, digestive, injury, musculoskeletal, 
genitourinary and neoplasms related comorbidities. After ANOVA and Student’s t-test with Bonferroni-
Holms correction of 101,766 patients treated with 21 diabetic medications, metformin, insulin, and 
repaglinide were found to be statistically significant at a 95% confidence level for the readmission 
categories. A multivariate logistics regression analysis was used to determine the early readmission 
influencing parameters and their risk levels. Following the analysis of the results, we conclude that: 
➢ The risk of early unplanned readmission of diabetic patients is higher for females treated with 
metformin, repaglinide, and insulin than males. 
➢ Patients whose medications were changed to metformin, insulin, and repaglinide are more susceptible 
to early unplanned readmission than those whose medications were not to the medications. 
Future studies 
We will test the remaining hypotheses (H2 and H3) and further explore the factors influencing < 30 
days readmission. This will be critically evaluated in the continuation of this study to fully understand their 
impacts thereby, allowing clinicians to focus on the key risk factors in developing strategic plans for 
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individualized management of comorbid diabetes patients. There is also the need to know the influence of 
the various comorbidities on the readmission likelihood to get a better judgement of the most vital therapy 
for managing them. Finally, the sensitivity of these risk factors will be established to know if there is any 
significant deviation in the readmission risks to facilitate the development of efficient strategic risk 
mitigation plans. 
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